<img alt="" height="1" width="1" />
GSK files melanoma drug combination early in race to market
LONDON | Tue Jul 9, 2013 3:12am EDT. LONDON (Reuters) - GlaxoSmithKline has filed for U.S. approval of a two-drug combination against melanoma earlier than many industry analysts expected, using data from a mid-stage clinical trial. The move ...
GSK Submits Supplemental NDAs To FDA For Dabrafenib/trametinib CombinationRTT News
GlaxoSmithKline seeks approval for melanoma drugsStock Market Wire
GLAXOSMITHKLINE PLC : US submission for BRAF/MEK combination therapy4-traders (press release)
Capital.gr (press release)
all 9 news articles &raquo;